|Articles|October 12, 2020
Assessing Multiple Critical Quality Attributes of Monoclonal Antibody and Comparability Assessments
Author(s)Agilent Technologies
Discover how LC/MS peptide mapping can be used to characterize and quantify different monoclonal antibody (mAb) critical quality attributes (CQAs).
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Year in Review: How FDA Guidances Defined the 2025 Biopharma Landscape
2
Biopharma’s 2025 Transformation: A Recap of Our Top 10 Articles
3
AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet
4
Top BP Videos of 2025: An Intersection of AI, Innovation, and Compliance
5